Merck & Co. Files 2Q25 10-Q Financial Report

Ticker: MRK · Form: 10-Q · Filed: 2025-08-05T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, financials, quarterly-report

TL;DR

Merck's 2Q25 10-Q is in. Get the latest financials.

AI Summary

Merck & Co., Inc. filed its 10-Q for the period ending June 30, 2025. The filing provides financial updates for the second quarter of 2025. Key financial details and operational information are presented as required by the SEC.

Why It Matters

This filing provides investors and analysts with the latest financial performance data for Merck & Co., Inc., crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: low — This is a routine quarterly financial filing and does not inherently present new risks.

Key Players & Entities

Merck & Co., Inc. (company) — Filer of the 10-Q
20250630 (date) — End of the reporting period
20250805 (date) — Filing date
221918501 (company) — EIN for Merck & Co., Inc.

FAQ

What is the reporting period for this 10-Q filing?

The reporting period for this 10-Q filing is the quarter ended June 30, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on August 5, 2025.

What is the company's Central Index Key (CIK)?

The CIK for Merck & Co., Inc. is 0000310158.

What is Merck & Co., Inc.'s fiscal year end?

Merck & Co., Inc.'s fiscal year ends on December 31.

What is the business address of Merck & Co., Inc.?

The business address is 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065.

From the Filing

0000310158-25-000014.txt : 20250805 0000310158-25-000014.hdr.sgml : 20250805 20250805161352 ACCESSION NUMBER: 0000310158-25-000014 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250805 DATE AS OF CHANGE: 20250805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 251185137 BUSINESS ADDRESS: STREET 1: 126 EAST LINCOLN AVENUE STREET 2: P.O. BOX 2000 CITY: RAHWAY STATE: NJ ZIP: 07065 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 126 EAST LINCOLN AVENUE STREET 2: P.O. BOX 2000 CITY: RAHWAY STATE: NJ ZIP: 07065 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-Q 1 mrk-20250630.htm 2Q25 FORM 10-Q (6.30.25) mrk-20250630 FALSE 2025 Q2 0000310158 12/31 http://fasb.org/us-gaap/2025#LongTermDebtNoncurrent http://fasb.org/us-gaap/2025#LongTermDebtNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsCurrent http://fasb.org/us-gaap/2025#OtherAssetsCurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsCurrent http://fasb.org/us-gaap/2025#OtherAssetsCurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2025#OtherNonoperatingIncomeExpense 24 xbrli:shares iso4217:USD iso4217:USD xbrli:shares mrk:candidate xbrli:pure mrk:interest_rate_swap mrk:case mrk:plaintiff mrk:company mrk:patent mrk:proceeding mrk:segment 0000310158 2025-01-01 2025-06-30 0000310158 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0000310158 mrk:A1.875Notesdue2026Member 2025-01-01 2025-06-30 0000310158 mrk:A3.250NotesDue2032Member 2025-01-01 2025-06-30 0000310158 mrk:A2.500Notesdue2034Member 2025-01-01 2025-06-30 0000310158 mrk:A1.375Notesdue2036Member 2025-01-01 2025-06-30 0000310158 mrk:A3.500NotesDue2037Member 2025-01-01 2025-06-30 0000310158 mrk:A3.700NotesDue2044Member 2025-01-01 2025-06-30 0000310158 mrk:A3.750NotesDue2054Member 2025-01-01 2025-06-30 0000310158 2025-07-31 0000310158 2025-04-01 2025-06-30 0000310158 2024-04-01 2024-06-30 0000310158 2024-01-01 2024-06-30 0000310158 2025-06-30 0000310158 2024-12-31 0000310158 2023-12-31 0000310158 2024-06-30 0000310158 mrk:VeronaPharmaPlcMember us-gaap:SubsequentEventMember 2025-07-01 2025-07-31 0000310158 mrk:HRS5346JiangsuHengruiPharmaceuticalsCo.Ltd.Member 2025-04-01 2025-06-30 0000310158 mrk:JiangsuHengruiPharmaceuticalsCo.Ltd.Member 2025-05-31 0000310158 mrk:WuXiVaccinesFacilityMember 2025-03-01 2025-03-31 0000310158 mrk:WuXiVaccinesFacilityMember us-gaap:AssetUnderConstructionMember 2025-03-31 0000310158 mrk:HarpoonTherapeuticsInc.Member 2024-03-01 2024-03-31 0000310158 mrk:HarpoonTherapeuticsInc.Member 2024-01-01 2024-06-30 0000310158 mrk:AstraZenecaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2025-01-01 2025-06-30 0000310158 mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArran